TY - JOUR
T1 - Antimicrobial Resistance in the COVID-19 Landscape
T2 - Is There an Opportunity for Anti-Infective Antibodies and Antimicrobial Peptides?
AU - Pérez de la Lastra, José M.
AU - Anand, Uttpal
AU - González-Acosta, Sergio
AU - López, Manuel R.
AU - Dey, Abhijit
AU - Bontempi, Elza
AU - Morales delaNuez, Antonio
N1 - Funding Information:
This research was funded by projects “Agencia Canaria de Investigación, Innovación y Sociedad de la Información (ACIISI) del Gobierno de Canarias” (project ProID2020010134), and CajaCanarias (project 2019SP43). MRL acknowledges contract (IMMUNOWINE) financed by Cabildo de Tenerife, Program TF INNOVA 2016-22 (with MEDI & FDCAN Funds). AMN is a recipient of a postdoctoral Marie Curie fellowship under grant agreement 101030604 (IGYMERA). The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.
Publisher Copyright:
Copyright © 2022 Pérez de la Lastra, Anand, González-Acosta, López, Dey, Bontempi and Morales delaNuez.
PY - 2022/6/2
Y1 - 2022/6/2
N2 - Although COVID-19 has captured most of the public health attention, antimicrobial resistance (AMR) has not disappeared. To prevent the escape of resistant microorganisms in animals or environmental reservoirs a “one health approach” is desirable. In this context of COVID-19, AMR has probably been affected by the inappropriate or over-use of antibiotics. The increased use of antimicrobials and biocides for disinfection may have enhanced the prevalence of AMR. Antibiotics have been used empirically in patients with COVID-19 to avoid or prevent bacterial coinfection or superinfections. On the other hand, the measures to prevent the transmission of COVID-19 could have reduced the risk of the emergence of multidrug-resistant microorganisms. Since we do not currently have a sterilizing vaccine against SARS-CoV-2, the virus may still multiply in the organism and new mutations may occur. As a consequence, there is a risk of the appearance of new variants. Nature-derived anti-infective agents, such as antibodies and antimicrobial peptides (AMPs), are very promising in the fight against infectious diseases, because they are less likely to develop resistance, even though further investigation is still required.
AB - Although COVID-19 has captured most of the public health attention, antimicrobial resistance (AMR) has not disappeared. To prevent the escape of resistant microorganisms in animals or environmental reservoirs a “one health approach” is desirable. In this context of COVID-19, AMR has probably been affected by the inappropriate or over-use of antibiotics. The increased use of antimicrobials and biocides for disinfection may have enhanced the prevalence of AMR. Antibiotics have been used empirically in patients with COVID-19 to avoid or prevent bacterial coinfection or superinfections. On the other hand, the measures to prevent the transmission of COVID-19 could have reduced the risk of the emergence of multidrug-resistant microorganisms. Since we do not currently have a sterilizing vaccine against SARS-CoV-2, the virus may still multiply in the organism and new mutations may occur. As a consequence, there is a risk of the appearance of new variants. Nature-derived anti-infective agents, such as antibodies and antimicrobial peptides (AMPs), are very promising in the fight against infectious diseases, because they are less likely to develop resistance, even though further investigation is still required.
KW - SARS-CoV-2
KW - antibiotic discovery
KW - antibiotic resistance
KW - antimicrobial peptides
KW - environmental contamination
KW - global health
KW - one health approach
KW - vaccination
UR - http://www.scopus.com/inward/record.url?scp=85132291631&partnerID=8YFLogxK
U2 - 10.3389/fimmu.2022.921483
DO - 10.3389/fimmu.2022.921483
M3 - Review article
C2 - 35720330
AN - SCOPUS:85132291631
VL - 13
JO - Frontiers in Immunology
JF - Frontiers in Immunology
SN - 1664-3224
M1 - 921483
ER -
